ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial
Alzheimer's disease (AD) is the most common cause of dementia, characterized by memory loss and cognitive impairments that interfere with daily life.
A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction contribute to cognitive decline in AD.
The phase 3 clinical trial aims to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.
The multicentre trial is taking place across nine clinical centres in Turkey, targeting patients with mild, moderate, and severe Alzheimer's symptoms.
Stockholm, Sweden - November 4, 2025- ScandiBio Therapeutics AB today announced the initiation of a multicentre, phase 3 human clinical trial evaluating the efficacy and safety of their pharmaceutical, Combined Metabolic Activator (CMA), in patients with Alzheimer's disease (AD).
Author's summary: ScandiBio starts phase 3 trial for Alzheimer's.
More News
- Elliott wins Gainesville City Council Ward 2 seat
- Study finds ultrashort-chain PFAS built up in Wilmington residents' blood before GenX scandal
- Zohran Mamdani Becomes New York's First Indian-American Muslim Mayor
- Stewart Wins Tight Gainesville Supervisor Race; Democrats Flip Prince William Board Seat
- Scarbinsky: Can Auburn turn it around when people who backed Hugh Freeze are still there?
- Zohran Mamdani wins NYC mayor’s race, capping a stunning ascent
- How to get a free NBA League Pass trial by using today’s DraftKings promo code
- 2025 East Cobb Election Results: Georgia PSC; Marietta City
- Save $1,100 USD on the Sony 1920GB CFexpress Type B TOUGH Memory Card - Newsshooter